Iurina N A, Sorokovoĭ V I, Romashova M F, Mochenova N N
Biull Eksp Biol Med. 1993 Feb;115(2):140-2.
The effects of eicosapentaenoic acid (EPA) and a new dihydropyridine calcium antagonist isradipine on plasma cholesterol free fatty acids (FFA) and erythrocytes have been studied in 48 cholesterol-fed rabbits after 3-month experiment. EPA had no statistically significant reduction of total cholesterol, FFA but showed the accumulation of cholesterol in plasma and altered morphological and functional properties of erythrocytes. Isradipine revealed a dose-dependent reduction of hypercholesterolemia. levels of FFA in plasma and improved functions of erythrocytes. In this way EPA may be suitable for dietary treatment of atherosclerosis, while isradipine may be used for therapy of patients with an antisclerotic vascular system and hyperlipidemia.
在一项为期3个月的实验后,对48只喂食胆固醇的兔子研究了二十碳五烯酸(EPA)和一种新型二氢吡啶类钙拮抗剂伊拉地平对血浆胆固醇、游离脂肪酸(FFA)和红细胞的影响。EPA对总胆固醇、FFA没有统计学上的显著降低作用,但显示出血浆中胆固醇的积累以及红细胞形态和功能特性的改变。伊拉地平显示出剂量依赖性的高胆固醇血症降低作用、血浆中FFA水平降低以及红细胞功能改善。通过这种方式,EPA可能适用于动脉粥样硬化的饮食治疗,而伊拉地平可用于治疗具有抗硬化血管系统和高脂血症的患者。